Background
- The American College of Rheumatology (ACR) guidelines recommends a treat-to-target approach in managing patients to a goal of remission/low disease activity, yet many rheumatology practices do not routinely assess or document RA disease activity due to time constraints and uncertainty about which measure to use.
- The RA Periodic Assessment of Disease Activity Quality Measure (#177) was updated to require assessment of RA disease activity at ≥ 50% of encounters for each RA patient during the measurement year.
- Treating Rheumatoid Arthritis to Target: 2015 Update of the Recommendations of an International Task Force, recommends: Disease activity assessments as frequently as monthly for patients in high/moderate disease activity and less frequently (3-6 months) when patients reach a target of remission or low disease activity.
- This Treat to Target (T2T) program seeks to demonstrate the impact of specialty pharmacy services in supporting T2T goals by engaging patients and delivering information to rheumatologists that can be used to improve patient outcomes utilizing the Routine Assessment of Patient Index Data 3 (RAPID3) Disease activity measurement.
Objectives
Leverage the capabilities of hospital-based specialty pharmacists and software to capture patient reported disease activity to collaborate with rheumatologists and enhance treatment management.
Read about the team's findings by downloading the Outcomes Study below.
Download the abstract: